Growing indication for FNA to study and analyze tumor heterogeneity at metastatic sites

2014 ◽  
Vol 122 (7) ◽  
pp. 504-511 ◽  
Author(s):  
Francisco Beca ◽  
Fernando Schmitt
2021 ◽  
Author(s):  
Li Chen ◽  
Biswajit Das ◽  
Yvonne A. Evrard ◽  
Chris A. Karlovich ◽  
Tomas Vilimas ◽  
...  

2019 ◽  
Author(s):  
Harini Veeraraghavan ◽  
H. Alberto Vargas ◽  
Alejandro-Jimenez Sanchez ◽  
Maura Miccó ◽  
Eralda Mema ◽  
...  

AbstractBackgroundHigh grade serous ovarian carcinoma shows marked intra-tumoral heterogeneity which is associated with decreased survival and resistance to platinum-based chemotherapy. Pre-treatment quantification of spatial tumor heterogeneity by multiple tissue sampling is not clinically feasible. Using standard-of-care CT imaging to non-invasively quantify heterogeneity could have high clinical utility and would be highly cost-effective. Texture analysis measures local variations in computed tomography (CT) image intensity. Haralick texture methods are typically used to capture the heterogeneity of entire lesions; however, this neglects the possible presence of texture habitats within the lesion, and the differences between metastatic sites. The primary aim of this study was to develop texture analysis of intra-site and inter-site spatial heterogeneity from standard-of-care CT images and to correlate these measures with clinical and genomic features in patients with HGSOC.Methods and findingsWe analyzed the data from a retrospective cohort of 84 patients with HGSOC consisting of 46 patients from Memorial Sloan Kettering Cancer Center (MSKCC) and 38 non-MSKCC cases selected from The Cancer Imaging Archive (TCIA). Inclusion criteria consisted of FIGO stage II–IV HGSOC, attempted primary cytoreductive surgery, intravenous contrast-enhanced CT of abdomen and pelvis performed prior to surgery and availability of molecular tumor data analysed as per the Cancer Genome Atlas (TCGA) Research Network ovarian cancer project. Manual segmentation and image analysis was performed on 463 metastatic tumor sites from 84 patients. In the MSKCC cohort the median number of tumor sites was 7 (interquartile range 5–9) and 4 (interquartile range 3–4) in the TCIA patients. Sub-regions were produced within each tumor site by grouping voxels with similar Haralick texture using the Kernel K-means method. We derived statistical measures of intra- and inter-site tumor heterogeneity (IISTH) including cluster sites entropy (cSE), cluster sites standard deviation (cluDev) and cluster sites dissimilarity (cluDiss) from sub-regions identified within and between individual tumor sites. Unsupervised clustering was used to group patient IISTH measures into low, medium, high, and ultra-high heterogeneity clusters from each cohort.The IISTH measure cluDiss was an independent predictor of progression-free survival (PFS) in multivariable analysis in both datasets (MSKCC hazard ratio [HR] 1.04, 95% CI 1.01–1.06, P = 0.002; TCIA HR 1.05, 95% CI 1.00–1.10, P = 0.049). Low and medium IISTH clusters were associated with longer PFS in multivariable analysis (MSKCC HR 2.94, 90% CI 1.29–6.70, P = 0.009, TCIA HR 5.94, 95% CI 1.05–33.6, P = 0.044). IISTH measures were robust to differences in the CT imaging systems. Average Haralick textures contrast (TCIA HR 1.08, 95% CI 1.01–1.10, P = 0.019) and homogeneity (TCIA HR 1.09, 95% CI 1.02–1.16, P = 0.008) were associated with PFS in mutivariate analysis only in the TCIA dataset. All other average Haralick textures and total tumor volume were not associated with PFS in either dataset.ConclusionsTexture measures of intra- and inter-site tumor heterogeneity from standard of care CT images are correlated with shorter PFS in HGSOC patients. These quantitative methods are independent of the CT imaging system and can thus be applied in clinical practice. The methodology proposed here enables the non-invasive quantification of intra-tumoral heterogeneity and disease stratification for future experimental medicine studies and clinical trials, particularly in cases where total tumour volume and averaged textures have low predictive power.Author summaryWhy was this study done?Tumor heterogeneity is a feature of many solid malignancies including ovarian cancer.Recent genomic research suggests that intra-site tumor heterogeneity (heterogeneity within a single tumor site) and inter-site tumor heterogeneity (heterogeneity between different metastatic sites in the same patient) correlate with clinical outcome in HGSOC.What did the researchers do and find?We developed quantitative and non-invasive image-analysis based measures for predicting outcome in HGSOC patients by combining image-based information from within and between multiple tumor sites.Using datasets from two sources, we demonstrate that these image-based tumor heterogeneity measures predict progression free survival in patients with HGSOC.What do these findings mean?Non-invasive measures of CT image heterogeneity may predict outcomes in HGSOC patients.Wider application of these CT image heterogeneity measures could prove useful for stratifying patients to different therapies given that total tumour volume and averaged textures have low predictive power.


Diagnostics ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 1555
Author(s):  
Caterina Fumagalli ◽  
Massimo Barberis

Breast tumor heterogeneity is a major challenge in the clinical management of breast cancer patients. Both inter-tumor and intra-tumor heterogeneity imply that each breast cancer (BC) could have different prognosis and would benefit from specific therapy. Breast cancer is a dynamic entity, changing during tumor progression and metastatization and this poses fundamental issues to the feasibility of a personalized medicine approach. The most effective therapeutic strategy for patients with recurrent disease should be assessed evaluating biopsies obtained from metastatic sites. Furthermore, the tumor progression and the treatment response should be strictly followed and radiogenomics and liquid biopsy might be valuable tools to assess BC heterogeneity in a non-invasive way.


2017 ◽  
Author(s):  
Benjamin D. Landry ◽  
Thomas Leete ◽  
Ryan Richards ◽  
Peter Cruz-Gordillo ◽  
Gary Ren ◽  
...  

ABSTRACTDue to tumor heterogeneity, most believe that effective treatments should be tailored to the features of an individual tumor or tumor subclass. It is still unclear what information should be considered for optimal disease stratification, and most prior work focuses on tumor genomics. Here, we focus on the tumor micro-environment. Using a large-scale co-culture assay optimized to measure drug-induced cell death, we identify tumor-stroma interactions that modulate drug sensitivity. Our data show that the chemo-insensitivity typically associated with aggressive subtypes of breast cancer is not cell intrinsic, but rather a product of tumor-fibroblast interactions. Additionally, we find that fibroblast cells influence tumor drug response in two distinct and divergent manners, which were predicable based on the anatomical origin from which the fibroblasts were harvested. These divergent phenotypes result from modulation of “mitochondrial priming” of tumor cells, caused by secretion of inflammatory cytokines, such as IL6 and IL8, from stromal cells.


2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 177-177
Author(s):  
Jeremy D. Kratz ◽  
Amani Gillette ◽  
Shujah Rehman ◽  
Aishwarya Sunil ◽  
Katherine Anne Johnson ◽  
...  

177 Background: No current clinical tool can predict the efficacy of cancer therapeutics for patients with colorectal cancer (CRC). We recently demonstrated the feasibility of using patient-derived cancer organoids (PDCOs) to examine therapeutic response and tumor heterogeneity for individual patients with CRC via optical metabolic imaging (OMI). Here we expand these analyses in a cohort of patients with clinical outcomes. Methods: CRC tissue was collected from patients on IRB-approved protocols. PDCOs were matured and treated with chemotherapy regimens concurrent with patient treatment. Previously established effect size response thresholds were used for diameter ( > 1.5) and OMI ( > 0.5) following 48 hours of treatment. OMI measures the intrinsic autofluorescence of NAD(P)H and FAD using 2-photon microscopy without specific reagents or dyes. Clinical outcomes were prospectively collected by manual chart review. Results: 12 CRC PDCOs were established from patients with CRC. PDCOs were collected from initial diagnosis and advanced setting of both primary and metastatic sites by core needle biopsy and surgical resection. Differential growth rates were observed across lines. PDCOs with RAS/RAF alterations had more uniform growth, while PDCOs without these alterations demonstrated more heterogeneous growth and metabolism. Clinical correlation of PDCOs response with recurrence of disease in the adjuvant setting will be presented. Cases with prior 5-FU-based chemotherapy at the time of PDCO collection had intermediate sensitivity. For PDCOs collected pre-treatment, PDCO response predicted clinical response for 5 of 6 cases using predefined sensitivity thresholds. In the case that overall PDCO response did not predict clinical response, a heterogenous response was observed with distinct sensitive and resistant populations. Across PDCOs, greater post-treatment heterogeneity was observed in resistant lines compared to those with treatment sensitivity. Conclusions: Tumor heterogeneity in treatment response can be assessed using PDCOs growth and metabolism. The utility of PDCOs to predict clinical outcomes for patients with CRC deserves further prospective validation.


1997 ◽  
Vol 36 (08) ◽  
pp. 282-288 ◽  
Author(s):  
T. Atasever ◽  
A. Özdemir ◽  
I. Öznur ◽  
N. I. Karabacak ◽  
N. Gökçora ◽  
...  

Summary Aim: Our goal was to determine the clinical usefulness of TI-201 to identify breast cancer in patients with suspicious breast lesions on clinical examination, and/or abnormal radiologic (mammography and/or ultrasonography) findings. Methods: TI-201 scintigraphy were performed in sixty-eight patients with 70 breast abnormalities (51 palpable, 19 nonpalpable) and compared with mammography and ultrasonography (US). Early (15 min) and late (3 h) images of the breasts were obtained following the injection of 111 MBq (3 mCi) of TI-201. Visual and semiquantitative interpretation was performed. Results: Final diagnosis confirmed 52 malignant breast lesions and 18 benign conditions. TI-201 visualized 47 of 52 (90%) overall malignant lesions. Thirty-eight of 40 (95%) palpable and 9 of 12 (75%) nonpalpable breast cancers were detected by TI-201 scintigraphy. The smallest mass lesion detected by TI-201 measured 1.5x1.0 cm. Eleven breast lesions were interpreted as indeterminate by mammography and/or sonography. TI-201 scintigraphy excluded malignancy in 7 of 8 (88%) patients with benign breast lesions interpreted as indeterminate. Five of the 18 (28%) benign breast lesions showed TI-201 uptake. None of the fibroadenoma and fibrocystic changes accumulated TI-201. TI-201 scintigraphy, mammography and ultrasonography showed 90%, 92%, 85% overall sensitivity and 72%, 56%, 61% overall specificity respectively. Twenty-one of the 28 (75%) axillary nodal metastatic sites were also detected by TI-201. In malignant and benign lesions, early and late lesion/contralateral normal side (L/N) ratios were 1.58 ± 0.38 (mean ± SD) and 1.48 ± 0.32 (p >0.05), 1.87 ± 0.65 and 1.34 ± 0.20 (p<0.05) respectively. The mean early and late L/N ratios of malignant and benign groups did not show statistical difference (p>0.05). Conclusion: Overall, TI-201 scintigraphy was the most specific of the three methods and yielded favourable results in palpable breast cancers, while it showed lower sensitivity in nonpalpable cancers and axillary metastases. Combined use of TI-201 scintigraphy with mammography and US seems to be useful in difficult cases, such as dense breasts and indeterminate breast lesions.


2019 ◽  
Author(s):  
Diana Tronik-Le Roux ◽  
Jérôme Verine ◽  
Alix Jacquier ◽  
Raluca Stanciu ◽  
Julie Renard ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document